北美 Glioblastoma 多种形式处理市场定义、分块、份额、范围和分析

北美多形性胶质母细胞瘤治疗市场，按类型（原发性（从头治疗）、继发性）、治疗（手术、放射治疗、药物）、患者类型（成人、老年人、儿童）、药物类型（仿制药、品牌药）、给药途径（肠外、口服、其他）、最终用户（医院、诊所、家庭医疗保健、其他）、分销渠道（医院药房、零售药房、网上药房、其他）划分 - 行业趋势和预测到 2029 年。

市场分析和见解

千兆多形式(GBM)是IV级的WHO恶性肿瘤,有天体细胞分化. 作为临床上诊断出最常见的中枢神经系统(CNS)肿瘤学条目之一,对这些肿瘤的描述和思想演变有各种各样的历史报告. 最早被记录的胶原体报告是在英国科学报告中给出的,由伯恩斯于1800年提供,由阿伯内蒂于1804年提供,由鲁道夫·维尔肖于1865年提供第一部综合性的形态学描述. 1926年,珀西瓦尔·贝利和哈维·克兴(英语:Harvey Cushing)为胶原虫的现代分类提供了基础. 在1934年至1941年间,胶原研究中最丰富的研究者是汉斯-约阿希姆·舍尔(Hans-Joachim Scherer),他假设了GBM的一些临床形态学方面. 随着分子和基因测试的被引入,GBM的真多相多相已经建立,不同的基因型具有相同的地貌学和IHC相片,以及一些光滑发作的方面. 一个GBM要开发,一个特定的触发突变需要在GBM干细胞中发生——主GBM,或单个突变的缓慢聚合,没有明显的触发突变——次GBM. 自200多年前首次描述这些恶性肿瘤以来,对GBM的知识一直与CNS的一般医学知识密切相关. 当时在CNS的脚步和一般医学知识的进步上,已经取得了几个巨大的飞跃. 对glioblastoma多形式处理的需求正在增加,制造商参与了新产品的发布,增加了管道产品和事件对市场的参与。这些决定最终会促进市场的增长。

Glioblastoma Multiforme Treatment Market

Glioblastoma多形式治疗市场报告详细介绍了市场份额、新动态、国内和地方市场参与者的影响,分析了新兴收入、市场监管变化、产品批准、战略决策、产品发布、地域扩张以及市场技术创新等方面的机会。为了了解分析和市场状况联系我们做一个分析员简报我们的团队将帮助你创造收入影响解决方案实现你期望的目标诸如合作、协议和签署销售协议等战略举措,以发明和创新药物治疗,是推动预测期间市场需求的主要因素。

Glioblastoma 多种形态治疗市场具有支持性,旨在减少疾病的发展。数据桥市场研究(Data Bridge Market Research)分析认为,在2022至2029年的预测期间,glioblastoma多形式治疗市场将以8.5%的CAGR增长.

报表计量	细节
预测期	2022至2029年统计
基准年	2021
历史年代	2020年(2019-2014年可定制).
数量单位	收入(百万美元),定价(美元)
覆盖部分	按类型(初级(De Novo)、中级)、治疗(外科、放射治疗、医疗)、病人类型(Adult、老年病、儿童)、药物类型(遗传学、品牌)、行政路线(Parenteral、口腔等)、最终用户(医院、诊所、家庭保健等)、分发渠道(医院药房、零售药房、在线药房等)
涵盖国家	美国、加拿大、墨西哥
覆盖的市场玩家	F. Hoffmann-La Roche AG、Amgen Inc.、Merck & Co.、Pfizer Inc.、Varian Medical Systems Inc.(Siemens保健公司的一个子公司)、ZEISS国际、Amneal Pharminics LLC、Elekta、Sun Pharminical Industries、Teva Pharminics Ltd.、Eckert & Ziegler、A协议保健、Angiochemem、ANI制药、Arbor Pharminics、LAC(A Assubit of Azurity Pharminics, Inc.)、AstraZeneca、Cantex制药公司、CELON LABS、DINS、DINC、EFC、EFINC、EDUS制药公司等。

市场定义

Glioblastoma多型(GBM)是最常见的并具有攻击性的初级恶性脑瘤,在成人中占脑瘤的60%. GBM可以在大脑中再生出或由下等的天体细胞瘤演化而来. 在成人中,GBM最常出现在大脑半球,尤其是大脑的前叶和时叶. 许多遗传因素和环境因素在glioblastoma多形态中进行了研究,但没有发现占GBM一大部分的风险因素. 因此,与其他许多癌症一样,GBM是零星的,虽然一些研究表明,GBM患者之前的治疗辐照率很高(17%). 辐照与GBM发展之间的间隔时间从几年到几十年不等. 没有确凿证据表明GBM与吸烟、酗酒、吸毒或接触N-Nitroso化合物等生活方式因素有关联。研究表明,使用手机不会增加GBM的发展风险;然而,其与长期使用的联系需要进一步确认.

多形式治疗市场动态

司机

Glioblastoma多种形态的日益流行

Glioblastoma multiforme (GBM) 是最常见的恶性原生脑瘤,占所有中枢神经系统(CNS)主要恶性肿瘤的77%-81%. 世界卫生组织将其归类为四等扩散性天体细胞瘤和寡头腺瘤. 初级GBM演示的平均年龄为62岁,中位存活期约为14.6个月. 与GBM有关的不良预后有充分的文件证明,尽管医学和外科手术取得了进展,但存活率仍然很低,令人失望。根据这项研究,国际研究表明,每年的发病率约为每10万人0.59至5起;然而,研究表明,发病率有所上升。 Miranda-Filho等人在2017年描述了南美,东欧和南欧国家氯化萘和脑癌发病率的上升,而只有日本报告了发病率的下降. Dobes等在2011年也注意到了GBM肿瘤在他们两个多中心澳大利亚研究中的发病率不断上升,前叶和时叶GBM肿瘤的发病率特别高. Glioblastoma多型菌的发病率增加,增加了利用最新技术进行早期检测和诊断的需求,推动了全球Glioblastoma多型菌治疗市场。全球各地高血糖瘤发病率的上升,预计会加快对高血糖瘤多种形态治疗的需求。因此,千兆瘤多型体发病率的上升可望促进市场的增长。

增加研究和开发(r和d)

增加分子生物技术和癌症及相关疾病的基因疗法方面的研发活动促进了各种生物药物的发展。这些药物有助于减少现有治疗方法的副作用,从而在病人中产生更广泛的接受。患者与患者之间治疗方法的肿瘤异质性和差异预计会增加对个性化治疗方法的需求,以管理glioblastoma多形式. 批准新的治疗方法,预计会提高患有高血压多型的病人的预期寿命。此外,林业发展局特别指定调查药物,预计会加快新疗法的批准程序和商业化。研究人员和市场参与者之间合作的增加预计将能促进开发出新型和有效治疗glioblastoma多形态的备选方案。越来越多的新疗法和复方疗法获得批准,预计会推动胶原虫多型治疗市场。

机会

增加药品批准

对glioblastoma多形式治疗的需求不断上升,应当对相关药物进行更多的监管批准。对相关药物和再生产品越来越多的监管认可,将构成未来几年胶原体多形式治疗市场价值的增加。在泛美卫生组织促进承认药品管制当局的倡议框架内,ANMAT的评价进程于2009年12月11日完成。近年来,由该疾病的死亡率不断上升所驱动的多型胶囊瘤治疗行业已获得众多药品批准。增加药品批准量将提升glioblastoma多形式治疗市场需求.

限制/挑战

Glioblastoma多形式治疗费用高

对glioblastoma多型的诊断测试包括技术高度先进的产品。开发这些产品需要发展中角色进行严格的研究和开发。因此,产品成本仍然很高,这按比例增加了测试成本.

用于诊断glioblastoma多形态的诊断工具和技术包括:

放射治疗,化疗等. 典型的GBM早期症状很少或没有;因此,GBM在后期经常被诊断出,导致预后差. 因此,使用先进模式和技术产品处理胶原瘤多型体的高昂成本将成为全球胶原瘤多型体处理市场增长的一个主要制约因素。

最近的事态发展

2022年4月,埃莱克塔和GE保健公司宣布,它们在辐射肿瘤学领域签署了全球商业合作协议,使它们能够为需要放射治疗的癌症患者提供跨成像和治疗的全面服务. 这种伙伴关系将使各公司能够共同促进解决每个癌症中心的需求。
2019年7月,Amgen和Allergan plc宣布美国(美国)有与Avastin(英语:Bevacizumab-awwb)相仿的生物活性物质MASI(英语:Bevacizumab). 这一推出将提高产品在该区域的销售量

多种形式治疗市场范围

Glioblastoma 多种形态治疗市场根据类型、治疗、病人类型、药物类型、管理路线、最终用户和分销渠道,分为七个值得注意的类别。各部门之间的增长有助于你分析特殊的增长领域和接近市场的战略,并确定你的核心应用领域和目标市场的差异。

类型

小学(德新)
中学

根据类型,glioblastoma多形式治疗市场分为初级(De Novo)和二级.

治疗

外科手术
放射治疗
药品

在治疗的基础上,胶囊瘤多型治疗市场分为外科、放射治疗和药物。

患者类型

成人
老年病
儿童

根据病人类型,胶原瘤多型治疗市场分为成人、老年和子女。

药物类型

品牌
常规

根据药物类型,glioblastoma多形式治疗市场被分出为通名并被打上品牌.

行政路线

口头
家长
其他人员

根据管理路线,glioblastoma多形式治疗市场被分割成亲、口等部分。

结束用户

医院
诊所
家庭保健
其他人员

在最终用户的基础上,glioblastoma多型治疗市场分为医院、诊所、家庭保健等。

分发频道

医院药房
零售药店
在线药店
其他人员

Glioblastoma Multiforme Treatment Market

根据分销渠道,glioblastoma多型治疗市场分为医院药房,零售药房等.

全球多形式治疗市场区域分析/见解

如上所述,按类型、治疗、病人类型、药物类型、管理路线、最终用户和分销渠道,对胶囊瘤多形式治疗市场进行了分析,提供了市场规模的见解和趋势。

Glioblastoma多形式治疗市场报告所涵盖的区域是美国、加拿大和墨西哥。

在北美,由于该疾病在该区域的流行率不断上升,预计美国会主导市场.

报告的国家部分还提供了影响市场的因素和影响市场当前和未来趋势的市场监管变化。下游和上游价值链分析,技术趋势和搬运工的五种力分析等数据点,案例研究是用来预测个别国家市场情景的一些指针. 此外,还考虑了全球品牌的存在和可得性及其由于来自当地和国内品牌的大规模或稀缺竞争而面临的挑战、国内关税和贸易路线的影响,同时对国家数据进行了预测分析。

竞争性景观和多形式治疗市场共享分析

Glioblastoma多形式治疗市场竞争情况提供了竞争者的详细信息。详细情况包括公司概况、公司财务、创收、市场潜力、研发投资、新市场举措、全球存在、生产地点和设施、生产能力、公司优势和弱点、产品推出、产品宽度和广度以及应用优势。上述数据点仅涉及公司对glioblastoma多形式治疗市场的关注。

市场上的一些关键角色有:F. Hoffmann-La Roche AG、Amgen Inc.、Merck & Co. Inc.、Pfize Inc.、Varian Medical Systems Inc.(Siemens保健公司的一个子公司)、ZEISS国际、Amneal制药有限责任公司、Elekta、Sun制药业有限公司、Teva制药工业有限公司、Eckert & Ziegler、Angiochem、ANI制药公司、Arbor制药公司、LLC(A Ssubers of Azurity Pharmaces, Inc.)、AstraZenca、Cantex制药公司、CELON LABS、DIF、ENIC、ERC.SA、Genenta科学、Jazz制药公司、Loxo Oncology、Nortis AG、VBLTHEUTICS、VATris和Zydus制药公司等。

研究方法

数据收集和基准年分析使用具有大样本规模的数据收集模块。利用市场统计和连贯一致的模式分析和估计市场数据。此外,市场份额分析和主要趋势分析是市场报告的主要成功因素. DBMR研究小组采用的关键研究方法是数据三角化,涉及数据挖掘、数据变量对市场的影响分析以及初级(工业专家)验证。除此之外,数据模型还包括供应商定位网格、市场时间线分析、市场概况和指南、公司定位网格、公司市场份额分析、计量标准、全球Vs区域和供应商份额分析。如有进一步调查,请联系分析师。

SKU-68253

在线获取全球首个市场情报云平台的报告访问权限

点击图片放大

交互式数据分析仪表板
用于发现高增长潜力机会的公司分析仪表板
研究分析师支持（定制与咨询）
带有交互式仪表板的竞争对手分析
最新新闻、更新与趋势分析
利用基准分析的强大功能，实现全面的竞争对手跟踪

申请演示

表格列表

TABLE 1 PIPELINE ANALYSIS FOR GLIOBLASTOMA MULTIFORME TREATMENT MARKET

TABLE 2 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA PRIMARY (DE NOVO) IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA SECONDARY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA SURGERY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA ADULTS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA CHILD IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA GENERICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA BRANDED IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA PARENTERAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA HOSPITAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA CLINICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA HOME HEALTHCARE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA HOSPITAL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA RETAIL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA ONLINE PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 43 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 44 NORTH AMERICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 45 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 46 NORTH AMERICA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 47 NORTH AMERICA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 48 NORTH AMERICA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 49 NORTH AMERICA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 50 NORTH AMERICA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 51 NORTH AMERICA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 52 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 53 NORTH AMERICA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 54 NORTH AMERICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 55 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 56 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 57 NORTH AMERICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 58 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 59 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 60 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 62 U.S. RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 63 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 64 U.S. TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 65 U.S. NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 66 U.S. CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 67 U.S. TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 68 U.S. ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 69 U.S. CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 70 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 71 U.S. ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 72 U.S. GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 73 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 74 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 75 U.S. ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 76 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 77 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 78 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 80 CANADA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 81 CANADA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 82 CANADA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 83 CANADA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 84 CANADA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 85 CANADA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 86 CANADA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 87 CANADA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 88 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 89 CANADA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 90 CANADA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 91 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 92 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 93 CANADA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 94 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 95 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 96 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 97 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 98 MEXICO RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 99 MEXICO MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 100 MEXICO TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 101 MEXICO NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 102 MEXICO CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 103 MEXICO TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 104 MEXICO ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 105 MEXICO CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 106 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 107 MEXICO ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 108 MEXICO GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 109 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 110 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 111 MEXICO ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 112 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 113 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET : DATA TRIANGULATION

FIGURE 3 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 INCREASE IN THE PREVALENCE OF GLIOBLASTOMA MULTIFORME AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 PRIMARY (DE NOVO) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN 2022 & 2029

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET

FIGURE 16 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2021

FIGURE 17 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 18 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 19 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2021

FIGURE 21 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2022-2029 (USD MILLION)

FIGURE 22 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, CAGR (2022-2029)

FIGURE 23 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, LIFELINE CURVE

FIGURE 24 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2021

FIGURE 25 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION)

FIGURE 26 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, CAGR (2022-2029)

FIGURE 27 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 28 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2021

FIGURE 29 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)

FIGURE 30 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, CAGR (2022-2029)

FIGURE 31 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 32 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 33 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 34 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 35 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 36 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2021

FIGURE 37 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 38 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, CAGR (2022-2029)

FIGURE 39 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 41 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 42 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 43 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 45 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021)

FIGURE 46 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 47 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 48 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE (2022-2029)

FIGURE 49 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY SHARE 2021 (%)

查看详细信息

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

常见问题

市场的增长率是多少?

在2029年的预测中,北美多形式治疗市场将增长8.5%。

市场增长繁荣的重要因素是什么?

北美Glioblastoma多形式治疗市场增长的重要因素是:glioblastoma多形式治疗的流行率不断上升,药品批准率不断提高。

谁是在市场上经营的主要角色?

在北美Glioblastoma多种形式治疗市场的主要参与者是: F. Hoffmann-La Roche AG、Amgen Inc.、Merck & Co.、Pfizer Inc.、Varian Medical Systems Inc.(Siemens保健公司的一个子公司)、ZEISS国际、Amneal Pharminics LLC、Elekta、Sun Pharminical Industries、Teva Pharminics Ltd.、Eckert & Ziegler、A协议保健、Angiochemem、ANI制药、Arbor Pharminics、LAC(A Assubit of Azurity Pharminics, Inc.)、AstraZeneca、Cantex制药公司、CELON LABS、DINS、DINC、EFC、EFINC、EDUS制药公司等。

市场覆盖的主要国家是什么?

北美多形式治疗市场覆盖的主要国家有:美国,加拿大,墨西哥.